ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

Core Insights - ImmuCell Corporation reported significant improvements in financial performance for the second quarter and six-month period ended June 30, 2025, including a net income of approximately $502,000 for the quarter and $1.9 million for the six months, contrasting with net losses in the same periods of 2024 [4][8]. Product Sales Highlights - Product sales for the second quarter of 2025 increased by 18% to approximately $6.4 million compared to the same quarter in 2024 [7]. - For the six-month period ended June 30, 2025, product sales rose by 14% to approximately $14.5 million compared to the same period in 2024 [7]. - Over the twelve-month period ended June 30, 2025, product sales increased by 22% to approximately $28.3 million compared to the previous year [7]. Financial Performance - Gross margin improved to 44% for the three-month period and 43% for the six-month period ended June 30, 2025, compared to 22% and 28% respectively in 2024 [8]. - Adjusted EBITDA improved to approximately $1.4 million, $3.7 million, and $5.3 million for the three-month, six-month, and twelve-month periods ended June 30, 2025, respectively [8][16]. Balance Sheet Strength - Cash and cash equivalents increased to approximately $6.0 million as of June 30, 2025, up from $3.8 million at the end of 2024 [8][14]. - Net working capital rose to approximately $12.7 million as of June 30, 2025, compared to $10.6 million at the end of 2024 [8][14]. - Stockholders' equity increased to approximately $29.9 million as of June 30, 2025, from $27.5 million at the end of 2024 [9]. Strategic Initiatives - The company has eliminated the backlog of orders as of June 30, 2025, and is building inventory to meet customer demand for the peak selling season [4]. - ImmuCell has initiated Investigational Product use for Re-Tain to collect market feedback on product performance during the second half of 2025 and into early 2026 [4].